Researchers at the Johns Hopkins Kimmel Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy have developed ...

Quarterly financial reports play a vital role on Wall Street, as they help investors see how a company has performed and what might be coming down the road in the near-term. And out of all of the ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

It has some rivals in its push to the IgG4-RD market, notably Amgen which ... Zenas licensed certain rights to the drug in Asia to Bristol-Myers Squibb for $50 million upfront plus undisclosed ...

Radiotherapy, China's biotech surge and AI's role in drug discovery are notable topics that emerged from conversations on the ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other safe stocks to buy for the long term in 2025. The US stock market is often ...

David Risinger’s rating is based on the impressive launch performance of Bristol-Myers Squibb’s Cobenfy, which is showing strong sales momentum since its introduction for schizophrenia treatment.

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other stocks discussed by Jim Cramer with insights on the DeepSeek AI sell-off.

In terms of shares owned, we count 4 of the above funds having increased existing BMY positions from 09/30/2024 to 12/31/2024, with 2 having decreased their positions and 4 new positions.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

View Bristol-Myers Squibb Company (BMY) current and estimated P/E ratio data provided by Seeking Alpha.